Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILLUMINATE: REGN13335 in Pulmonary Arterial Hypertension
NCT07318597Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2026
- Primary completion
- Feb 2028
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of regn13335 in pulmonary arterial hypertension (PAH) (5 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Pulmonary Vascular Resistance at 24 weeks. Started May 2026; status: recruiting.
02
Drugs
regn13335
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07318597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318597.